Agios Pharmaceuticals, Inc. (LON:0HB0)

Market Cap	1.23B
Revenue (ttm)	28.66M
Net Income (ttm)	515.47M
Shares Out	n/a
EPS (ttm)	8.86
PE Ratio	2.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	31
Open	29.12
Previous Close	28.97
Day's Range	29.12 - 29.12
52-Week Range	20.13 - 35.35
Beta	n/a
RSI	45.53
Earnings Date	May 1, 2025

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2007
• Employees: 488
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HB0

Financial Performance

Financial numbers in USD